Thus, the immune checkpoint based therapy targeting PD-1 and PD-L1 have recently been approved for their use in patients with different malignant conditions, including melanoma and lung and renal cancer27, and it is very feasible that this type of immunotherapy could be useful in other many tumors, including GEP-NETs28. The gene discussed is CD274; the disease is melanoma.